RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Trillium Therapeutics Stock

Trillium Therapeutics P/S 2024

Trillium Therapeutics P/S

0

Ticker

TRIL.TO

ISIN

CA89620X5064

WKN

A12FG3

As of Sep 29, 2024, Trillium Therapeutics's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Trillium Therapeutics P/S history

Trillium Therapeutics Aktienanalyse

What does Trillium Therapeutics do?

Trillium Therapeutics Inc is a Canadian biotech company specializing in the development of cancer treatments. The company was founded in 2005 and is based in Mississauga, Ontario. Trillium Therapeutics is involved in various areas of research. One of its key focuses is the development of immunotherapies for cancer treatment. The company is working on the discovery and development of novel targeted immunotherapies that aim to specifically target tumors and utilize the body's immune system to fight cancer. Another focus of Trillium Therapeutics is the development of cancer drugs targeting specific gene mutations. These drugs are intended to inhibit or kill cancer cells by specifically targeting the genetically altered cells. Trillium Therapeutics is also involved in the discovery and development of drugs for the treatment of immuno-oncological diseases, which are diseases where the body's immune system fights against its own cells, such as autoimmune diseases. The business model of Trillium Therapeutics is based on the research and development of innovative cancer drugs. The company collaborates closely with leading cancer centers and clinics to identify and test new therapeutic approaches. Trillium Therapeutics has a number of products and therapies in development. One example is TTI-621, an immunotherapy that aims to recognize and kill tumor cells. TTI-621 is currently in clinical trials for the treatment of T-cell lymphomas and glioblastomas, a type of brain tumor, and has shown promising results. Another product that Trillium Therapeutics is working on is TTI-622. It is also an immunotherapy that focuses on inhibiting T-cells to support controlled tumor growth. TTI-622 is currently in clinical trials in patients with advanced cancer. The company is also working on a number of preclinical programs aimed at expanding treatment options for cancer patients. These programs target various biological targets, including immunomodulation, induction of apoptosis, and inhibition of DNA repair. Trillium Therapeutics has received several awards and recognitions in recent years, including inclusion in the Russell 3000 Index, being named the top biotechnology company on the BioCentury Future Leaders List, and being recognized as one of the top 10 most exciting biotech companies in Canada. Overall, Trillium Therapeutics is a leading biotech company focused on the development of innovative cancer therapies. The company is at the forefront of technology and collaborates closely with leading cancer centers and clinics to develop products that can improve the lives of cancer patients. Trillium Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Trillium Therapeutics's P/S Ratio

Trillium Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Trillium Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Trillium Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Trillium Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Trillium Therapeutics stock

What is the price-to-earnings ratio of Trillium Therapeutics?

The price-earnings ratio of Trillium Therapeutics is currently 0.

How has the price-earnings ratio of Trillium Therapeutics changed compared to last year?

The price-to-earnings ratio of Trillium Therapeutics has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Trillium Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Trillium Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Trillium Therapeutics affect the company?

An increase in the price-earnings ratio of Trillium Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Trillium Therapeutics affect the company?

A decrease in the price-earnings ratio of Trillium Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Trillium Therapeutics?

Some factors that influence the price-earnings ratio of Trillium Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Trillium Therapeutics pay?

Over the past 12 months, Trillium Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Trillium Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Trillium Therapeutics?

The current dividend yield of Trillium Therapeutics is .

When does Trillium Therapeutics pay dividends?

Trillium Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Trillium Therapeutics?

Trillium Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Trillium Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Trillium Therapeutics located?

Trillium Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Trillium Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Trillium Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Trillium Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Trillium Therapeutics in the year 2023?

In the year 2023, Trillium Therapeutics distributed 0 USD as dividends.

In which currency does Trillium Therapeutics pay out the dividend?

The dividends of Trillium Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Trillium Therapeutics

Our stock analysis for Trillium Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Trillium Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.